EuropaBio elects new chairman Andrea Rappagliosi to lead Association

25.06.2009

Brussels, 25 June 2009
 

At its Annual General Assembly held June 24th in Brussels, EuropaBio, the European Association for Bioindustries, elected Dr. Andrea Rappagliosi (1) Vice President European Government Affairs & Head of Brussels Office, GlaxoSmithKline, to Chair the Association over the next two years. He succeeds Mr. Steen Riisgaard, President and CEO, Novozymes A/S , who has completed his mandate but will stay on as a Board Member. 
 
Dr. Andrea Rappagliosi joined the EuropaBio Board in 2004 and was appointed at the Executive Committee in 2005. In the last four years, he chaired the Healthcare Council of the Association and represented EuropaBio at the European Commission High Level Pharmaceutical Forum. 
 
“We need to be courageous and drive changes to ensure that in Europe we utilize the full potential of biotechnology in order to overcome the important challenges imposed by the financial, economic and social crisis that we are currently facing” – says Dr. Andrea Rappagliosi, Chairman of EuropaBio – “By strengthening the European biotechnology sector's competitiveness, we will build a solid foundation for a wealthy and healthy society in Europe, where citizens can live better and longer. This sector can play an important part in progress towards Europe’s goal of economic growth, social prosperity and solidarity.”. 
 
In welcoming the new chairman, Mr. Willy De Greef, Secretary General of EuropaBio said: “We are delighted to have a strong believer in our industry who will continue to bring his passion to the cause of biotechnology. Andrea will be a dynamic Chairman and will build further on the strengths of the association.” In addition to new Board Members (2), the association also elected Mr. Thomas Bols, Director Government Affairs, Europe, Amgen, as Chair of the Healthcare Council and Dr. Detlef Niese, Head of External Affairs, Global Development, Novartis, as Vice-Chair for Science. Additionally, Mr. Jan Wisse, Managing Director of the Netherlands' Biotech Industry Association (NIABA), was elected Chair of the National Associations’ Council. 
 
EuropaBio is the EU association representing the biotechnology industry across a wide number of industrial sectors (3), including health, agri food and industrial processes. The association has been at the forefront of developing policies to grow a strong biotechnology sector in Europe.
 
 
ENDS
 
 
For further information, contact
 
 
Andrea Campbell,
 
Tel: +32 2 739 1161
 
(Direct) Mobile: +32 473 213 868
 
 
 
 
Notes to Editors
 
(1) Biography of Andrea Rappagliosi
 
Born in Rome, Andrea Rappagliosi received a law degree from the University of Rome “La Sapienza” andcompleted a post-graduate Masters at the Istituto Superiore dei Studi Legislativi (ISLE) from which he obtained a “Legislative Consultant Diploma”. 
 
He began his career in the early eighties, first in the Italian Government as a member of staff for the State Undersecretary of the Treasury, then for the Italian Senate focused on drafting of legislative texts, comparative legal studies and public budget analysis. 
 
In 1992, he moved into healthcare and worked for The Ares-Serono Group as Head of the Institutional Affairs Department in charge of the Rome and Brussels offices. From 1995 to 1999, he was Public Affairs Director at Baxter Healthcare, part of the European Public Affairs team. In 1999, he returned to Serono International, today Merck Serono International, as Vice President Health Policy & Market Access Europe. 
 
In April 2009, Andrea joined GlaxoSmithKline as Vice President European Government Affairs & Head of Brussels Office.
 
  • From 2005 to 2008, he has been member of the European Commission High Level Pharmaceutical Forum representing EuropaBio, the European Association for Bioindustry.
  • He sits on the Board of the Foundation of the European Platform for Patients Organizations, Science & Industry (EPPOSI). 
  • He is member of HTAi (the International Society of Health Technology Assessment) and founding member of its Policy Forum. 
  • He has been Industry representative at the EMEA/COMP (European Medicines Evaluation Agency/ Committee for Orphan Medicinal Products) Working Group with Interested Parties in the first two terms 2000 to 2005. 
  • He is member of the British Institute of International and Comparative Law and is a member of the Editorial Board of the Journal of Commercial Biotechnology
 
(2) New EuropaBio Board of Management (as of June 24h 2009)
 
 
 
About EuropaBio
EuropaBio's mission is to promote an innovative and dynamic biotechnology based industry in Europe. EuropaBio, (the European Association for Bioindustries), has 68 corporate and 7 associate members operating worldwide, 4 Bioregions and 25 national biotechnology associations representing some 1800 small and medium sized enterprises.
 
 

Latest Press releases